“…Thus, the pharmacological inhibitors of H 2 S-synthesizing enzymes did not show consistent outcomes, due to selectivity and dose- and time-adjustment issues [ 85 ]. Accordingly, molecular genetics therapeutic tools such as microRNAs (miRNAs), short hairpin RNAs (shRNAs), and small interfering RNAs (siRNAs) provide promising approaches that would allow for the specific targeting of H 2 S-synthesizing enzymes [ 79 , 84 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 ]. The following part of the review focuses on the possible mechanisms through which such RNA-based molecular genetics targeting approaches could be used and delivered to brain tumors.…”